Incretin Atlas › Trials › Ribupatide in obesity + PMOS (NCT06595797)
Ribupatide in obesity + PMOS (NCT06595797)
Ribupatide (HRS9531) · obesity
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- obesity
- Phase
- 2
- Participants
- 158
- Duration
- 32 weeks
- Registry
- NCT06595797
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 mg | obesity china | 32 | 158 | — | −10.0 % vs −2.6 % Δ −7.4 pp | — | 0.0 vs 0.0 | — | — | — | 0.0 vs 0.0 | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (3)
- 1 mg · weight_tp · abstract
mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1
- 1 mg · ae_dc · abstract, Results (last sentences)
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
- 1 mg · sae · abstract, Results (last sentences)
No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Ribupatide in obesity + PMOS (NCT06595797). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-in-obesity-pmos/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.